| Description | CU-CPT-9a is a potent TLR8 inhibitor (IC50 : 0.5 nM), that suppresses TLR8-mediated proinflammatory signaling in various cell lines and human primary cells- |
| Target activity | TLR8:0.5 nM |
| molecular weight | 265.31 |
| Molecular formula | C17H15NO2 |
| CAS | 2165340-32-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 150 mg/mL (565.38 mM) |
| References | 1. Zhang S , Hu Z , Tanji H , et al. Small-molecule inhibition of TLR8 through stabilization of its resting state[J]. Nature Chemical Biology, 2017, 14(1):58-64. |
| Citations | 1. Yang W, Sun X, Liu S, et al.TLR8 agonist Motolimod-induced inflammatory death for treatment of acute myeloid leukemia.Biomedicine & Pharmacotherapy.2023, 163: 114759. |